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ABSTRACT
The efficient delivery of the hepatitis C virus (HCV)
RNA subgenomic replicon into cells is useful for
basic and pharmaceutical studies. The adenovirus
(Ad) vector is a convenient and efficient tool for
the transduction of foreign genes into cells in vitro
and in vivo. However, an Ad vector expressing the
HCV replicon has never been developed. In the
present study, we developed Ad vector containing
an RNA polymerase (pol) I-dependent expression
cassette and a tetracycline-controllable RNA pol
I-dependent expression system. We prepared a
hybrid promoter from the tetracycline-responsive
element and the RNA pol I promoter. Ad vector par-
ticles coding the hybrid promoter-driven HCV
replicon could be amplified, and interferon, an in-
hibitor of HCV replication, reduced HCV replication
in cells transduced with the Ad vector coding HCV
replicon. This is the first report of the development
of an Ad vector-mediated HCV replicon system.
INTRODUCTION
Hepatitis C virus (HCV) is a member of Flaviviridae that
contains a 9.6-kb positive-sense RNA genome. A total of
170-million people worldwide are infected with HCV,
leading to chronic hepatic inﬂammation, hepatic ﬁbrosis,
hepatic cirrhosis and hepatocellular carcinoma (1).
Chronic infection with HCV is a major cause of
hepatocellular carcinoma (1). Interferon (IFN) therapy is
the gold standard method for HCV patients, but it is ef-
fective in only 50% of patients and its use has been limited
because of severe side effects (2–4). Additional pharma-
ceutical therapies are needed to overcome HCV. However,
the tropism of HCV is limited to chimpanzees and
humans, and the mechanism of HCV infection and repli-
cation is not fully understood. The HCV genome encodes
a polyprotein precursor of about 3000 amino acids that is
cleaved into at least 10 proteins: core, envelope 1 (E1), E2,
p7, non-structural protein 2 (NS2), NS3, NS4A, NS4B,
NS5A and NS5B (5). An HCV subgenome replicon
(called HCV replicon in the present study) consisting of
a reporter gene and HCV NS genes has allowed various
studies of HCV replication and the development of
anti-HCV agents (6–8). The delivery of the HCV
genome or HCV replicon is a powerful tool for basic
and pharmaceutical research, and the transduction of
in vitro translated HCV RNA genome is often performed
by electroporation. However, a convenient and efﬁcient
method to transfer the 9.6-kb HCV RNA genome or the
8–9-kb HCV replicon has never been fully developed.
Transcribed RNAs are classiﬁed into rRNAs, mRNAs
and short RNAs (tRNAs) in mammalian cells. RNA poly-
merases differ among the transcribed RNA species: RNA
polymerase (pol) I for rRNAs, RNA pol II for mRNA
and RNA pol III for short RNAs. RNA pol I transcribes
RNA without a 50-cap structure or a 30-poly-A tail, and a
plasmid vector encoding RNA pol I promoter and termin-
ator has been applied to the development of RNA
virus-expression system. For instance, inﬂuenza viruses,
arenavirus and uukuniemi viruses are generated using
RNA pol I-driven expression plasmid vectors coding
each segment of negative-sense RNA (9–12).
Recombinant adenovirus (Ad) vectors have been widely
used to deliver foreign genes to a variety of cell types and
tissues in vitro and in vivo in basic research and clinical
therapy. Ad vector can be easily prepared, grown to a high
titer, and used to efﬁciently transfer genes into dividing
and non-dividing cells. Furthermore, several types of Ad
vectors have been developed to expand their tropism and
to increase the size of encoded genes (13,14). Ad vector
encoding RNA pol I-driven expression of inﬂuenza virus
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seed strains and for basic inﬂuenza virus studies (15).
These ﬁndings indicate that the RNA pol I Ad vector
system can be a promising tool for basic and pharmaceut-
ical studies on HCV. However, the development of an
RNA pol I-driven vector system expressing the HCV
RNA genome has never been reported.
In the present study, we developed an RNA pol I-driven
vector system to monitor HCV replication using an HCV
replicon in which structural genes were replaced by the
luciferase gene. We prepared an Ad vector containing a
tetracycline (tet)-regulated RNA pol I-expression cassette
consisting of an RNA pol I-driven responsive vector and a
trans-activator vector, and we successfully developed an
Ad vector-mediated HCV replication system.
MATERIALS AND METHODS
Cell culture
Huh7.5.1 1bFeo [genotype 1b HCV replicon cell line, (8)]
were cultured in Dulbecco’s modiﬁed Eagle’s medium sup-
plemented with 10% fetal calf serum (FCS) and G418
(Nacalai Tesque, Kyoto, Japan) at 500mg/ml. Huh7 and
293 cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% FCS. The cells were
maintained in a 5% CO2 atmosphere at 37 C.
Preparation of RNA pol I-driven plasmid vectors
An RNA pol I expression-cassette was subcloned as
follows: pHH21 (kindly provided by Dr Kawaoka,
Tokyo, Japan) containing RNA pol I expression cassette
was digested with AﬂIII, blunted by the Klenow fragment
of DNA polymerase, ligated with EcoRI linker and
digested with EcoRI/NheI, resulting in a fragment of the
RNA pol I expression-cassette. The RNA pol I cassette
was inserted into the EcoRI-XbaI site of pHM5 (16),
generating pPol I. A fusion gene of enhanced green ﬂuor-
escent protein and ﬁreﬂy luciferase (EGFPLuc, Clontech,
Mountain View, CA, USA) was inserted into pPol I, re-
sulting in pPIWT-EL.
The subgenomic HCV sequence and the
replication-incompetent subgenomic HCV sequence
deleting GDD motif (MLVNGDDLVV) in NS5B were
ampliﬁed by polymerase chain reaction (PCR) using
pRepFeo as a template (8). The PCR fragments were
inserted into pPol I, generating pPol I-1bFeo and pPol
I-1bFeoGDD. The Feo fragment in pPol I-1bFeo or
pPol I-1bFeoGDD was replaced with ﬁreﬂy luciferase,
generating pPol I-HCV or pPol I-GDD coding ﬁreﬂy
luciferase reporter, HCV NS3, NS4A, NS5A and NS5B
or mutated NS5B, respectively. A plasmid expressing
b-galactosidase, pCMVb, was purchased from Marker
Gene Inc. (Eugene, OR, USA).
Preparation of tet-controllable RNA pol I-driven
plasmid vectors
To develop the tet-controllable RNA pol I promoter ex-
pression system, the minimal cytomegalovirus promoter
was replaced by fragments of RNA pol I promoters
(from  235 to  1, from  311 to  1 or from  412 to
 1) in pHM5-TREL2 (17), generating pPI235, pPI311 or
pPI412. These RNA pol I plasmid vectors were used for
optimization of the tetracycline responsive element
(TRE)/RNA pol I chimeric promoter. pHM5-tTA,
pHM5-rtTA and pHM5-TREL2 were used in
tet-regulated experiments (17).
Preparation of Ad vector expressing HCV replicon
The HCV replicon fragments cloned from pPol I-HCV or
pPol I-GDD were inserted into pPI235, and then the
ﬁreﬂy luciferase was replaced by the renilla luciferase to
form pPI235-HCV or pPI235-GDD. Ad vectors were
constructed by an improved in vitro ligation method
(18). Brieﬂy, pPI235-EL, pPI235-HCV and
pPI235-GDD were digested with I-CeuI and PI-SceI,
and then ligated with I-CeuI/PI-SceI-digested pAdHM4
and pAdHM36, respectively. The resulting plasmids
were digested with PacI and transfected into 293 cells
with SuperFect (Qiagen, Valencia, CA, USA).
AdPI235-EL, AdPI235-HCV and AdPI235-GDD were
puriﬁed by CsCl2 gradient centrifugation and dialyzed
with a solution containing 10mM Tris-HCl (pH 7.5),
1mM MgCl2 and 10% glycerol. The multiplicity of infec-
tion (MOI) of Ad vectors was measured using an
Adeno-X rapid titer kit (Clontech). Ad-tTA vectors were
prepared as previously described (17).
Expression of plasmid-based HCV replicon
Huh7 cells were transfected with 0.8mg of pPol I-HCV.
After 24h of incubation, the cells were lysed in LCb (Toyo
Ink, Tokyo, Japan). The cell lysates were frozen-thawed
and centrifuged at 32000g for 5min. The luciferase
activity in the resulting supernatant was measured using
a commercially available kit (PicaGene; Toyo Ink).
Inhibition assays of HCV replication in plasmid- or
Ad-based RNA pol I HCV system
Huh7 cells were transfected with 0.8mg of pPol I-HCV
and 0.2mg of pCMVb or infected with AdPI235-HCV
(10 MOI) and Ad-tTA (50 MOI). After 2.5 or 1.5h of
transfection, the cells were treated with recombinant
human interferon-a8 (IFN-a8) at the indicated concentra-
tion. After an additional 72 h of incubation, the cells were
lysed in LCb. Luciferase activity and b-galactosidase
activity in the lysates was measured with PicaGene and
a Luminescent b-gal Kit (Takara Bio Inc., Shiga,
Japan), respectively. The cell viability was measured with
a WST-8 kit according to the manufacturer’s instruction
(Nacalai Tesque).
Evaluation of tetracycline-controllable promoters in
plasmid vector
Huh7 cells were co-transfected with 0.1mg of reporter
plasmid (pPI235-EL, pPI311-EL, pPI412-EL or pPIWT-
EL), 0.8mg of tet-responsive trans-activator plasmid
(pHM5-rtTA in the tet-on system or pHM5-tTA in the
tet-off system) and 0.1mg of pCMVb. After 2.5h, the
cells were treated with doxycycline (Dox) at the indicated
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b-galactosidase activities in the lysates were measured.
Expression of Ad vector containing tetracycline-
controllable promoter system
Huh7 cells were transfected with a reporter Ad vector
(AdPI235-EL or AdPI235-HCV at MOI of 5 or 10) and
a trans-activator vector (Ad-tTA at MOI of 10 and 50).
After an additional 48h of incubation, luciferase activity
in the cell lysates was measured.
Western blotting
Huh7 cells were co-infected with AdPI235-HCV at
10 MOI and Ad-tTA at 50 MOI. The cells were lysed in
RIPA buffer [50 mM Tris-HCl (pH 7.4), 1% Nonidet
P-40, 0.25% sodium deoxycholate, 150mM NaCl, 1mM
EDTA] containing a cocktail of protease inhibitors
(Sigma, St Louis, MO, USA). The cell lysates (30mgo f
protein) were subjected to sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE), followed by
western blotting onto a polyvinylidene diﬂuoride
membrane (Millipore, Bedford, MA, USA). After
blocking in 5% skim milk, the ﬁlter was incubated with
mouse anti-NS5A (Meridian Life Science, Sacao, ME,
USA) or anti-b-actin Ab (Sigma). Then, the peroxidase-
labeled secondary antibodies were added. The
immunoreactive bands were visualized by chemilumines-
cence reagents (GE Healthcare, Buckinghamshire, UK).
Evaluation of NS5B-dependent replication
Huh7 cells were transfected with AdPI235-HCV or
AdPI235-GDD at 3 MOI and Ad-tTA at 15 MOI.
After 24h, the cells were treated with 10mg/ml of Dox
for 48h. Then, luciferase activities in the lysates were
measured.
Detection of a fragment of the HCV negative strand RNA
Huh7 cells were co-infected with AdPI235-HCV or
AdPI235-GDD at 3 MOI and Ad-tTA at 15 MOI.
After 24h, the cells were treated with 10mg/ml of Dox
for 48h. The total RNAs were puriﬁed with High Pure
RNA Isolation kit (Roche, Mannheim, Germany). The
RNAs were reverse-transcribed to cDNA using a commer-
cial available kit [TaKaRa RNA PCR Kit (AMV) Ver.
3.0] and a primer for the HCV negative strand RNA
(50-GCCAGCCCCCGATTGGGG-30) or a primer for
GAPDH (50-TCTACATGGCAACTGTGA-30), respect-
ively. The transcription products of NS3 and GAPDH
were ampliﬁed by PCR using paired primers (50-ATGG
CGCCTATTACGGCC-30 and 50-TGGTCTACATTAG
TGTAC-30) and (50-GGTGGTCTCCTCTGACTTCAA
CA-30 and 50-GTGGTCGTTGAGGGCAATG-30), re-
spectively. The putative sizes of the PCR products were
242-bp for NS3 and 89-bp for GAPDH. The PCR
products were separated on 2% agarose gel.
RESULTS
RNA pol I-driven plasmid vector
First, we constructed an RNA pol I-driven plasmid coding
an HCV replicon in which structural coding genes were
replaced by the luciferase gene (Figure 1A). To investigate
the expression of the HCV replicon from the RNA pol I
plasmid vector, we transfected the plasmid vector into
Huh7 cells. As shown in Figure 1B, the luciferase
activity was observed in the RNA pol I vector-transfected
cells. IFN is the most popular agent used to inhibit HCV
replication. To examine whether the RNA pol I plasmid
vector functions as an assay system for anti-HCV activity,
we investigated the effect of IFN on the expression of the
HCV replicon in the RNA pol I plasmid-transfected Huh7
cells. IFN dose-dependently reduced the replication of the
HCV genome (Figure 1C), reaching 29.2% of the control
at 5pg/ml. IFN treatment did not cause any cytotoxicity
(Figure 1D). These data suggest that the RNA pol I
plasmid coding the HCV replicon works as an assay
system for HCV replication.
RNA pol I-driven Ad5 vector
The Ad vector is the most efﬁcient gene transfer vector
for a variety of mammalian cells in vitro and in vivo
(13,14,19,20). There are more than 51 serotypes of Ad.
The Ad type 5 (Ad5) vector has been frequently used in
basic research and clinical studies (21). Ad5 vectors are
100- and 1000-fold more efﬁcient at mediating gene
transduction than cationic lipids, an effective non-viral
vector (22). A reverse genetics system for the generation
of inﬂuenza virus using RNA pol I-driven Ad5 vector
produced 1000-fold the virus titer of the RNA pol I
plasmid system (15). These ﬁndings indicate that the
Ad5 vector may have advantages for the preparation of
an HCV replicon system. We prepared RNA pol I-driven
Ad5 vectors and conﬁrmed the expression of a reporter
gene from the Ad5 vectors coding luciferase
(Supplementary Figure S1). However, we did not
succeed in preparing Ad5 vector particles coding the
HCV replicon. Indeed, there have been no previous
reports of the preparation of Ad5 vector expressing the
HCV RNA genome.
We think that two problems must be solved in order to
develop Ad5 vectors coding the HCV RNA genome.
These problems are the inﬂuence of the HCV replicon
on the preparation of Ad5 particles and the packaging
limit of Ad5 vectors.
Preparation of the TRE/RNA pol I chimeric promoter
The tet-regulated system comprises a regulator vector that
expresses tet-controlled trans-activators and a response
vector consisting of TRE within the promoter that
controls expression of the gene of interest. The
tet-controlled trans-activators are classiﬁed into tTA and
rtTA that binds to the TRE promoter and activates ex-
pression from the TRE promoter in the absence and
presence of Dox, respectively (23,24). We speculated that
a tet-regulated vector system would minimize the inﬂuence
of the HCV replicon on the preparation of Ad vector
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TRE and the RNA pol I promoter. As shown in
Figure 2A, the RNA pol I promoter is a 412-bp
fragment containing an upstream control element (UCE)
and the binding site of a transcription factor (Core). We
constructed three chimeric promoter-driven plasmid
vectors and checked the expression proﬁles using
luciferase as a reporter gene. The chimeric vector was
co-transfected into Huh7 cells with response vectors
coding tTA or rtTA (23,24). As shown in Figure 2B and
C, co-transfection with tTA exhibited a higher expression
level than that of rtTA. The PI235 promoter had the
lowest luciferase expression in the absence of response
vectors (Supplementary Figure S2). We used tTA and
the PI235 promoter in further studies. To investigate
whether the chimeric RNA pol I promoter works in the
Ad vector, we prepared Ad5 vector coding the chimeric
RNA pol I-driven luciferase gene. AdPI235-EL (MOI of
5) was co-transduced with Ad-tTA at MOI of 10 and 50.
As shown in Figure 2D, the luciferase expression was
increased in an Ad-tTA concentration-dependent manner.
Expression of the HCV replicon from Ad vector
The packaging limit of a foreign gene in the conventional
Ad5 vector has been estimated to be 8.1–8.2-kb (25). The
HCV replicon is  8.9-kb and contains a 1.7-kb ﬁreﬂy
luciferase gene and sequence derived from the HCV
genome. Thus, another reason for no previous reports re-
garding the preparation of Ad5 vector coding the HCV
replicon appears to be the packaging limit of the Ad5
vector. Mizuguchi and Hayakawa found that Ad5/35
vector containing chimeric ﬁbers of Ad5 and Ad35
increased the size limit of foreign genes to 8.8-kb (26).
We were successful in preparing Ad5/35 vector particles
(9.53 10
8IFU/ml) coding the TRE/RNA pol I chimeric
promoter-driven HCV replicon containing the 1.0-kb
renilla luciferase gene and sequence derived from the
HCV genome (Figure 3A). To investigate the expression
of the HCV replicon, Huh7 cells were transfected with the
Ad vector coding the HCV replicon and Ad-tTA at MOI
of 10 and 50, respectively. As shown in Figure 3B, western
blot analysis showed that NS5A was expressed in Huh7
cells transfected with the vectors in the absence of Dox.
Figure 1. Preparation of plasmid expressing HCV replicon driven by RNA pol I promoter. (A) Schematic construct of HCV replicon-expression
cassette. The HCV replicon gene was driven by the RNA pol I promoter (PI) and terminator (TI). (B) Transgene expression in Huh7 cells. Cells were
transfected with pPol I-HCV. After 24h of transfection, the luciferase activities were measured. Data are mean±SD (n=3). (C and D) Effect of
IFN on HCV replication in RNA pol I vector-transfected cells. Huh7 cells were transfected with pPol I-HCV. After 2.5h of transfection, the cells
were treated with IFN at the indicated concentration. After an additional 72h of incubation, the luciferase activity (C) and the cell viability (D) were
measured. The luciferase activity (%) was calculated as a percentage of that in the vehicle-treated cells. Data are mean±SD (n=3).
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dose-dependently attenuated expression of luciferase
(Supplementary Figure S3). To discriminate between
translation of the RNA pol I-transribed HCV RNA
derived from the vector DNA and translation of HCV
RNA derived from autonomous HCV replication in the
transcribed cells, we prepared replication-incompetent
HCV replicon deleting GDD motif in NS5B. Luciferase
expression was attenuated in the cells transfected with the
GDD-deleted Ad vector (AdPI235-GDD) (Figure 3D).
A fragment of the HCV negative strand RNA, an essential
replication intermediate, ampliﬁed by RT-PCR has been
detected in the cells transfected with AdPI235-HCV but
not AdPI235-GDD (Figure 3E). Autonomous replica-
tion of the HCV RNA may occur in this system. To
evaluate whether the Ad vector systems could be used to
evaluate inhibitors of HCV replication, we investigated
the effect of IFN on luciferase expression from HCV
replicon in the Ad vector. As shown in Figure 3F, treat-
ment of cells with 5pg/ml of IFN reduced luciferase ex-
pression (33.3% of vehicle-treated cells). Cell viability was
not affected by IFN treatment (Figure 3G). These ﬁndings
indicate that the tet-controllable RNA pol I Ad vector
may be useful for evaluation of anti-HCV activity.
DISCUSSION
HCV is an RNA virus containing the positive strand of a
9.6-kb RNA genome. A technique to transfer all or part of
the HCV RNA genome to cells could be widely applicable
for basic studies on HCV and pharmaceutical therapy
against HCV. However, efﬁcient and convenient
methods to transduce the HCV RNA genome have
never been fully developed. Electroporation of in vitro
translated HCV RNA genome into cells is the most
popular method. In the present study, we used a
tet-controllable expression system to successfully develop
an Ad vector system expressing the HCV RNA genome.
To our knowledge, development of Ad vector express-
ing HCV subgenome or genome has never been succeeded.
The NS3 protease is essential for processing most of the
NS proteins from the HCV polyprotein (27–30). The
cleavage site of the NS3 protease is estimated to be
between the P1 and P10 position of an acidic amino acid
at the P6 position, a Cys or Thr residue at the P1 position,
and a Ser or Ala residue at the P10 position (31). E1A,
pIIIa, pol and V proteins of Ad have the cleavage site of
the NS3 protease. The lack of previous success in
generating Ad vectors coding the HCV genome and
subgenome might be partly due to the degradation of
Ad components by the NS3 protease during the prepar-
ation of Ad particles. In the tet-regulated system, when Ad
vectors coding foreign genes driven by the TRE hybrid
promoter are co-transfected with tTA or rtTA vector,
the foreign gene can be expressed. Expression of the
foreign gene could be suppressed during ampliﬁcation of
Ad vector particles in 293 cells, resulting in the prepar-
ation of Ad vector particles. The critical factor in the HCV
replicon must be determined in a future study.
Figure 2. Development of tet-controllable RNA pol I promoter.
(A) Construct of the chimeric RNA pol I promoter. The 412-bp
human RNA pol I promoter contains Core (from  40 to  1), the
binding site of the transcription factor, and UCE (from  235 to
 130). TRE is connected to the full or partial RNA pol I promoter
at the indicated sites, resulting in PI235, PI311 and PI412. (B and C)
Promoter activities of the chimeric promoter in Huh7 cells. Huh7 cells
were co-transfected with the chimeric RNA pol I plasmid coding
EGFPLuc, pCMVb and trans-activator plasmid [rtTA (B) or tTA
(C)]. After 2.5h of transfection, the cells were treated with Dox at
the indicated dose. After an additional 48h of incubation, the luciferase
and b-galactosidase activities were measured. The luciferase activity was
normalized by the b-galactosidase activity and expressed relative to
that of pPIWT-EL-transfected cells. Data are mean±SD (n=3).
(D) Transgene activity of Ad vector coding the chimeric promoter con-
struct. Huh7 cells were co-infected with AdPI235-EL and Ad-tTA. The
MOI ratio of AdPI235-EL to Ad-tTA was 5:10 or 5:50. After an add-
itional 48 h of incubation, the luciferase activity was measured. Data
are the mean±SD (n=3).
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promoter (PI235) and the HCV replicon to monitor HCV replication as the luciferase expression. (B) Expression of HCV NS5A protein in Huh7 cells
transfected with AdPI235-HCV. The cells were transfected with AdPI235-HCV (10 MOI) and Ad-tTA (50 MOI). After 72h of incubation, the cells
were harvested, and the lysates (30mg) were subjected to SDS–PAGE, followed by immunoblotting with antibody against NS5A. Huh7 cells and
Huh7.5.1 1bFeo cells were used as the negative and positive controls, respectively. Lane 1, Huh7 cells; lane 2, Huh7 cells infected with
AdPI235-HCV; lane 3, Huh7.5.1 1bFeo cells. (C) Expression of luciferase in the Ad vector-transfected cells. Huh7 cells were co-infected with
AdPI235-HCV (10 MOI) and 0 or 50 MOI of Ad-tTA. After an additional 48h of incubation, the luciferase activity was measured. Data represent
the mean±SD (n=3). (D) Involvement of NS5B in expression of luciferase in the Ad vector-transfected cells. Huh7 cells were infected with
AdPI235-HCV or AdPI235-GDD (3 MOI) and Ad-tTA (15 MOI). After 24h, the cells were treated with 10mg/ml of Dox for 48h. Then, the
luciferase activity was measured. Data represent the mean±SD (n=3). (E) Expression of minus-stranded HCV RNA in the Ad vector-transfected
cells. Huh7 cells were co-infected with AdPI235-HCV or AdPI235-GDD at 3 MOI and Ad-tTA at 15 MOI. After 24h, the cells were treated with
10mg/ml of Dox for 48h. Then RT-PCR analysis was performed for detection of minus-stranded HCV NS3 and GAPDH. The PCR products were
separated on 2% agarose gel. Huh7 cells and Huh7.5.1 1bFeo cells were used as the negative and positive controls, respectively. Lane 1, Huh7 cells;
lane 2, Huh7.5.1 1bFeo cells; lane 3, Huh7 cells infected with AdPI235-GDD; lane 4, Huh7 cells infected with AdPI235-HCV. (F and G) Effect of
IFN on the replication of HCV replicon. Huh7 cells were infected with AdPI235-HCV (10 MOI) and Ad-rtTA (50 MOI). After 1.5h of infection, the
cells were treated with IFN at the indicated concentration for 72h. Then, the luciferase activity (F) and the cell viability (G) were measured. Data
represent the percentage of vehicle-treated cells. Data are the mean±SD (n=3).
e64 Nucleic Acids Research, 2011,Vol. 39,No. 10 PAGE 6 OF 8Transgenes delivered by a conventional Ad5 vector are
limited to a size of 8.1–8.2-kb (32), and the size of HCV
replicon is  8.2-kb (containing a 1.0-kb luciferase gene
and a 7.2-kb fragment of HCV genome) (8). The lack of
a successful preparation of Ad5 vector may be partly due
to limitation of packaging transgene. Mizuguchi and
Hayakawa prepared a chimeric Ad vector containing
type 5 and type 35 ﬁber proteins, which is a package
8.8-kb of foreign gene (26). CD46 is a receptor for Ad
type 35 (Ad35), and CD46 is ubiquitously expressed in
human cells (33,34). The Ad5/35 chimera vector can trans-
duce various human cells more effectively than Ad5
vectors, indicating that the Ad5/35 vector may be a
better system than Ad5 (26,35). In this study, we success-
fully prepared an Ad5/35 vector coding a tet-regulated
RNA pol I-driven HCV replicon, and we found that the
Ad5/35 vectors could be applied to evaluation of
anti-HCV activity.
In conclusion, to the best of our knowledge, this is the
ﬁrst report to establish a novel strategy for the preparation
of Ad vector expressing the HCV genome by using a
tet-controllable expression system. Replication-
incompetent HCV particles will be a promising candidate
for vaccine therapy for HCV. As mentioned above, the
packaging size (8.8-kb) of Ad5/35 vector used in the
present study is smaller than that of the HCV RNA
genome (9.6-kb), and, therefore, the preparation of
inactive HCV particles using Ad5/35 vector is impossible.
Helper-dependent Ad vector (HDAd), in which all viral
coding sequences are deleted, can deliver a large capacity
of  37-kb to cells (36). Tet-controllable RNA pol I HDAd
vector might contribute to the development of vaccine
therapy for HCV.
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